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A miRNA signature predicts benefit from addition of
hypoxia-modifying therapy to radiation treatment in
invasive bladder cancer
Mairah T. Khan1, Joely J. Irlam-Jones1, Ronnie Rodrigues Pereira2, Brian Lane1, Helen R. Valentine1, Kai Aragaki3, Lars Dyrskjøt4,5,
David J. McConkey3, Peter J. Hoskin1, Ananya Choudhury1 and Catharine M. L. West 1
BACKGROUND: miRNAs are promising biomarkers in oncology as their small size makes them less susceptible to degradation than
mRNA in FFPE tissue. We aimed to derive a hypoxia-associated miRNA signature for bladder cancer.
METHODS: Taqman miRNA array cards identified miRNA seed genes induced under hypoxia in bladder cancer cell lines. A
signature was derived using feature selection methods in a TCGA BLCA training data set. miRNA expression data were generated for
190 tumours from the BCON Phase 3 trial and used for independent validation.
RESULTS: A 14-miRNA hypoxia signature was derived, which was prognostic for poorer overall survival in the TCGA BLCA cohort
(n= 403, p= 0.001). Univariable analysis showed that the miRNA signature predicted an overall survival benefit from having
carbogen–nicotinamide with radiotherapy (HR= 0.30, 95% CI 0.094–0.95, p= 0.030) and performed similarly to a 24-gene mRNA
signature (HR= 0.47, 95% CI 0.24–0.92, p= 0.025). Combining the signatures improved performance (HR= 0.26, 95% CI 0.08–0.82,
p= 0.014) with borderline significance for an interaction test (p= 0.065). The interaction test was significant for local relapse-free
survival LRFS (p= 0.033).
CONCLUSION: A 14-miRNA hypoxia signature can be used with an mRNA hypoxia signature to identify bladder cancer patients
benefitting most from having carbogen and nicotinamide with radiotherapy.
British Journal of Cancer (2021) 125:85–93; https://doi.org/10.1038/s41416-021-01326-9
BACKGROUND
A treatment for locally advanced muscle invasive bladder cancer
(MIBC) patients is bladder preservation trimodality therapy
involving complete transurethral resection of bladder tumour
(TURBT) followed by radiotherapy (RT) with a radiosensitiser.1,2 The
largest trials investigating the potential of combining RT with
radiosensitisers were the Bladder Carbogen Nicotinamide (BCON)
and the Bladder Cancer 2001 (BC2001) trials.1 The BCON trial
randomised patients to RT alone or with hypoxia-modifying
carbogen and nicotinamide (RT+CON) and showed that the
combined treatment improved the 3-year overall survival rate by
13%.1,3 BC2001 randomised patients to RT alone or with
chemotherapy (5 fluorouracil and mitomycin C) and showed that
the combined treatment improved the 2-year locoregional
disease-free survival rate by 13%.1,4 Different radiosensitising
approaches are used, and as high levels of tumour hypoxia are
associated with a poor prognosis irrespective of the treatment
approach,5 a predictive hypoxia biomarker would help select
patients for RT with hypoxia-modifying therapy rather than
chemo-radiotherapy.2,6 Work from our group showed that
necrosis, CA9, hypoxia-inducible factor (HIF)-1α and a 24-gene
mRNA signature predict benefit for giving CON with RT in
BCON.3,7–9 The presence of tumour hypoxia is an adverse
prognostic feature irrespective of treatment, and we also showed
that high 24-gene signature scores associated with a poor
prognosis in patients with MIBC who did not receive RT.9
microRNAs (miRNAs) are 20–23 bp long single-stranded RNA
gene regulators,10,11 which have been validated as diagnostic and
prognostic biomarkers in oncology.12–16 miRNAs are more stable
than mRNA in formalin-fixed paraffin-embedded (FFPE) samples
due to their small size, making miRNA expression levels in FFPE
samples easier to detect.17 miRNA hypoxia signatures have not
been developed for bladder cancer. Six miRNAs identified in
hypoxia experiments in bladder cancer cell lines were reported to
have potential as a non-muscle invasive bladder cancer (NMIBC)
hypoxia-associated miRNA signature.18 These six miRNAs were
identified through experiments in cell lines, but no association
with prognosis or prediction in clinical data sets was shown.18
Among other cancer types, a three-miRNA hypoxia-related
signature was recently shown to be prognostic in colorectal
cancer.19 Given the potential of miRNAs as biomarkers in FFPE
samples, we aimed to develop a miRNA hypoxia signature in MIBC
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and compare its performance to our previously developed 24-
gene mRNA signature.9
METHODS
Cell culture and hypoxia experiments
Bladder cancer cell lines (T24, UMUC3, RT4, J82) were purchased
from the American Type Culture Collection (Manassas, VA, USA).
Cells were grown in RPMI-1640 with L-glutamine (Thermo Fisher
Scientific, Paisley, UK) supplemented with 10% foetal calf serum
(Sigma-Aldrich, Dorset, UK). Cell lines were authenticated using
the Promega Powerplex 21 system (Chilworth, UK) and tested for
mycoplasma at the Molecular Biology Core Facility, CRUK
Manchester Institute. Cells were seeded in 75-cm2 flasks to obtain
60% confluency after 48 h under normoxia. After 24 h in normoxia,
media were changed and cells cultured in parallel in normoxia and
hypoxia (0.2% and 1% O2) for a further 24 h. Hypoxia was obtained
using the Whitley H35 Hypoxystation (Don Whitley Scientific
Limited, Bingley, UK). Experiments were carried out in biological
triplicate.
Identification of differentially expressed miRNAs
Taqman miRNA array A cards (Thermo Fisher Scientific) were used
to identify miRNAs. The array A cards cover 384 well-characterised
miRNAs along with negative and endogenous controls (miRBase
version 22). Data were generated for all four cell lines grown in
0.2% O2 and 21% O2 and for the three MIBC cell lines (T24, J82,
UMUC3) grown in 1% O2.
RNA was extracted using the miRvana RNA Isolation Kit (Thermo
Fisher Scientific) and cleaned using the Norgen RNA concentration
and clean-up kit (Norgen Biotek Corp, Elmhurst, UK) following the
manufacturer’s instructions. In all, 100 ng of RNA from each
sample was reverse transcribed using the miRNA reverse
transcription kit and primers specific for the array cards as per
the manufacturer’s instructions. The cards were run on a
Quantstudio 12K (Applied Biosystems, Foster, CA, USA) and
analysed with a normalisation threshold (Rn) of 0.2. Ct value ≥30
across all three normoxia and hypoxia triplicates were excluded
from analysis as recommended.
Data were normalised using the geometric mean of the array
card endogenous controls (RNU48, RNU44, U6snRNA) or occa-
sionally the geometric mean of one or two controls if that
increased the stability of values across the samples. Data were
analysed using the ΔΔCt method with mean fold changes (2^
(−ΔΔCt)) calculated. p Values were obtained using an unpaired t
test with Welch correction as used previously in other studies.20,21
Differentially expressed miRNAs were identified as having p values
<0.05 (unpaired t test with Welch correction) and fold changes
>1.0. A false discovery rate (FDR) cut-off was considered too
stringent for the analysis due to the high intra-group variation and
hence was not applied.
Development of the miRNA signature
miRNAs induced (i.e. upregulated) with fold change >1.0 under
0.2% hypoxia in ≥2 bladder cancer cell lines were used as seed
genes to derive a signature. The Cancer Genome Atlas (TCGA)
bladder cancer (BLCA) mature miRNA-seq counts (n= 409) were
downloaded from GDCRNATools22 and normalised to reads per
million mapped (RPM) counts. TCGA BLCA mRNA data—RNA-Seq
by Expectation-Maximisation (RSEM) normalised counts (n= 408)
—were downloaded from Firebrowse (http://firebrowse.org). RPM
and RSEM values with a pseudo-count of 1 added were log2
transformed. There were 405 TCGA BLCA patients who had both
miRNA-seq and mRNA-seq data. The 405 TCGA BLCA patients
were split 70:30 into the training and test cohorts balanced for the
proportion of hypoxia classifications (Supplementary Table 1).
Overall survival (OS) data were available for 403 of the 405
patients and progression-free survival (PFS) data were available for
404 of the 405 patients.
The Boruta algorithm23 was used in the training data set to
identify miRNAs important in predicting hypoxic and normoxic
tumours defined using the Winter 99-gene hypoxia signature24
(Supplementary Methods). Spearman correlations were calculated
between the expression levels of the miRNAs identified and
Winter signature scores and those significant were selected for the
miRNA signature. miRNA signature scores were calculated as
mean (miRNAs positively correlated with the Winter hypoxia
scores)−mean (miRNAs negatively correlated with the Winter
hypoxia scores).
The online tool miRWalk base 2.0 was used to select miRNA
targets predicted by three target prediction databases: miRWalk,
TargetScan, and miRDB.25 Gene enrichment analysis was carried
out on the predicted targets in the MiRWalk database.
miRNA expression cohorts
miRNA-seq (GSE84525) and mRNA (GSE48075) data were available
for 62 MIBC patients generated from fresh frozen bladder tumour
samples obtained during TURBT.26,27 miRNA microarray expression
data were also available for 106 bladder cancer patients (79
NMIBC, 27 MIBC) generated from samples acquired during
surgery.28 No material was shared between institutions. Expression
data for 829 miRNAs were generated for 192 patients randomised
in the BCON trial (96 RT and 96 RT+CON) using the NanoString
NCounter miRNA assay (NanoString Technologies, Seattle, WA,
USA) according to the manufacturer’s instructions. Two samples
were excluded as they did not pass all the quality control metrics.
Further details on the processing of the NanoString generated
data are available in the Supplementary Methods. Log2-trans-
formed normalised counts of 190 samples in the BCON cohort
were used for analyses. The clinico-pathologic details of the 190
BCON patients are shown in Supplementary Table 2.
Statistical analysis
The Cox regression model was used for univariable and multi-
variable analyses and to generate hazard ratios (HRs) and 95%
confidence intervals (CIs). Log-rank test and Wald statistic
compared differences in univariable and multivariable analyses,
respectively. Variables with p value <0.1 were used in the
multivariable analysis models. Data were censored at 5 years.
The R package survival (v 3.1–12) was used for Cox analyses.29 The
R package survminer (v 0.4.6) was used to plot Kaplan–Meier
curves.30 Data analyses were carried out using R version 3.6.1 (R
core team, Vienna, Austria) or GraphPad Prism 7 (San Diego,
CA, USA).
Immunohistochemistry generated CAIX, Glut-1 and HIF-1α
protein expression data were available for the BCON cohort from
a previous study.8 The non-parametric Mann-Whitney U test was
used to compare median expression levels of CAIX, Glut-1 and HIF-




Previously used approaches for developing hypoxia signatures
involved using well-known hypoxia-induced genes (seed genes)
from cell lines.31–34 A similar approach was used for the
development of the miRNA hypoxia signature. Candidate seed
miRNAs were identified based on differential expression analysis
of cell lines cultured under normoxia and hypoxia. Prostate,
sarcoma and lung signatures were derived after identifying seed
genes using cell lines exposed to 1% O2.
33,34 However, 0.2% O2,
which is radiobiologically relevant, was used to select seed genes
by others.32,35
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An initial comparison compared miRNAs induced in the three
MIBC cell lines (T24, J82 and UMUC3) exposed to 0.2% and 1% O2.
There were very few differentially expressed miRNAs in 1% O2
versus 0.2% O2 in the MIBC cell lines (Supplementary Table 3).
Hence, for the fourth NMIBC cell line (RT4), array cards were only
run for cells grown in 0.2% O2. Supplementary Table 3 shows that
41–64 miRNAs were induced at 0.2% O2 in the cell lines. The
numbers of miRNAs induced at 0.2% O2 in at least 2, 3 and 4 cell
lines were 62, 26 and 3. miR-210-3p, miR-15b-5p and miR-99b-5p
were induced in all the four cell lines. The 62 miRNAs induced in
≥2 cell lines were taken forward as seed genes (Supplementary
Table 4).
Development and validation of a miRNA hypoxia signature
TCGA was used to develop a miRNA signature as it has the only
large BLCA cohort with both miRNA and mRNA data. Hypoxia-
associated miRNAs were previously identified by using mRNA
signatures to classify hypoxic tumours.36,37 Therefore, the same
approach was used here to filter the in vitro hypoxia-associated
miRNAs and identify those most relevant in terms of their ability to
classify patient tumours as hypoxic. We considered using the
Winter, Buffa, Lendahl and Chi mRNA signatures.24,31,38,39 Our 24-
gene bladder mRNA hypoxia signature was not used as it was
trained on prognosis in the TCGA BLCA data set,9 and would
classify miRNAs associated with not only hypoxia but also a poor
prognosis in our TCGA training data set. The Winter signature was
selected as it was the only one of the four signatures that was
prognostic for OS in the TCGA BLCA data set (HR= 1.50, 95% CI
1.11–2.03, p= 0.008). The Winter signature is not a bladder-
specific signature, being neither predictive nor prognostic in
BCON,9 but it was chosen as it should identify the bladder-specific
miRNAs associated with hypoxia both in in vitro and patient
samples. Before applying a feature selection method to select the
most robust miRNAs for classification, 3 (miR-18b-5p, miR-579-3p,
miR-597-5p) of our 62 seed miRNAs were excluded based on
having no/low expression across the TCGA BLCA samples.
Applying the Boruta algorithm to the TCGA BLCA training data
set (n= 284) identified 19 of the 59 seed miRNAs as important in
predicting the Winter signature classification of hypoxia (Fig. 1).
Fourteen of the 19 miRNAs correlated significantly with Winter
hypoxia scores (Table 1) and were taken forward for validation as a
signature. These 14 miRNAs were in the top 20 based on Gini
importance ranking of the 59 miRNAs.
Stratifying the 14 miRNA signature by quartiles initially showed
a median cut-off worked the best for PFS (HR= 1.71, 95% CI
1.20–2.45, p= 0.0027) and OS (HR= 1.41, 95% CI 0.99–2.02, p=
0.056) in the training data set (Fig. 2a, c and Supplementary
Table 5). Similar trends were seen in multivariable analyses
(Supplementary Table 5). In the TCGA BLCA test data set (n= 121),
the miRNA signature showed a trend for PFS (HR= 1.75, 95% CI
0.94–3.27, p= 0.074) but was not prognostic for OS (HR= 1.53,
95% CI 0.84–2.76, p= 0.16) (Fig. 2b, d and Supplementary Table 6).
In the multivariable analyses, the miRNA signature showed a trend
for OS; PFS was not tested as none of the clinical variables had
p values <0.1 (Supplementary Table 6).
Validation in external cohorts
Prognostic significance of the 14-miRNA signature was explored in
a cohort of 62 MIBC patients. The signature was prognostic for OS
(HR= 2.56, 95% CI 1.19–5.48, p= 0.01) and disease-specific
survival (HR= 2.57, 95% CI 1.15–5.73, p= 0.02). Multivariable
analyses were not significant (Supplementary Table 7). Use of an
upper quartile for stratification improved the performance of the
signature (Supplementary Fig. 1). For comparison, the results of
analyses of the Yang mRNA hypoxia signature are shown in
Supplementary Fig. 1. The Yang signature gave prognostic
significance only when stratified by the lower quartile (Supple-
mentary Table 7).
NanoString miRNA expression data were successfully generated
for 190 out of 192 samples (95 RT and 95 RT+CON) available from
patients in the BCON trial. The median cut-off in the BCON cohort
did not predict benefit of having CON with RT for local relapse-
free survival (LRFS; HR= 0.79, 95% CI 0.46–1.36, p= 0.40) and OS
(HR= 0.77, 95% CI 0.45–1.34, p= 0.40). Using the upper quartile
identified in the 62-patient cohort, the 14-miRNA signature
predicted benefit of having CON with RT for LRFS (HR= 0.45,
95% CI 0.21–1.01, p= 0.048; Fig. 3a) and OS (HR= 0.44, 95% CI
0.19–1.00, p= 0.044; Fig. 3c) for patients classified as hypoxic. The
benefit from CON was not significant in multivariable analyses for
the patients classified as hypoxic for LRFS (HR= 0.53, 95% CI
0.24–1.19, p= 0.13) and OS (HR= 0.54, 95% CI 0.23–1.25, p= 0.15)
(Supplementary Table 8). In patients classified as normoxic, there
was no benefit from having CON (Fig. 3b, d). The interaction
between the treatment arms and hypoxia status was borderline
significant for LRFS (p= 0.06) and OS (p= 0.08). None of the
individual miRNAs predicted benefit from CON (Supplementary
Table 9).
The signature was not prognostic in the individual treatment
arms of BCON for LRFS and OS (Supplementary Fig. 2). There were
no statistically significant associations of the miRNA hypoxia/
normoxia categories with clinico-pathologic variables except that
hypoxic tumours had higher protein expression of CAIX (p=
0.0043) and HIF-1α (p= 0.015; Supplementary Table 10).
Predicted targets of the miRNAs in the signature
mRNA target prediction for the 14 miRNAs in the signature
identified 676 protein-coding genes. Reactome pathway analysis
of the predicted miRNA targets showed that the top 10 most
enriched pathways involved phosphoinositide-3 kinase (PI3K)/Akt
signalling, regulation of transcription of phosphatase and tensin
homologue (PTEN) and RUNX1 and oncogene-induced cell
senescence (Table 2). Other enriched Reactome pathways (FDR
< 0.05) were ‘Oxidative Stress Induced Senescence’, ‘VEGFA-
VEGFR2 Pathway’, ‘Cyclin D-associated events in G1’ and
‘MAPK6/MAPK4 signalling’.
Performance of miRNA signatures in NMIBC
We had access to a miRNA profiled cohort for bladder cancer
patients (n= 106), with most having NMIBC (n= 79). Expression
profiling for one of the miRNAs in the signature (miR-224-5p) was
not available and the signature score was calculated with the
remaining 13 miRNAs. Values for miR-21-5p were missing for one
of the NMIBC patients. Hence, 105 of the patients were used for
the analyses. The signature was not prognostic for OS when
stratified by the median (HR= 1.16, 95% CI 0.63–2.15, p= 0.63) or
the upper quartile (HR= 1.33, 95% CI 0.69–2.57, p= 0.39).
We also assessed the performance of the six-miRNA hypoxia-
regulated NMIBC cell line signature. The signature was prognostic
in the mainly NMIBC patient cohort (OS; HR= 2.26, 95% CI
1.19–4.30, p= 0.011) using 5 of the 6 miRNAs (no data available
for miR-708-5p) when the signature was summarised by mean
expression and patients stratified by the upper quartile.
Comparing the miRNA signature with the Yang mRNA signature
Figure 4 shows the results of analyses of the 130 patients in BCON
with both miRNA and mRNA signature scores. The miRNA
signature predicted benefit from having CON for LRFS (HR=
0.35, 95% CI 0.12–1.02, p= 0.043) and OS (HR= 0.30, 95% CI
0.094–0.95, p= 0.030) in the 26 of the 130 patients it classified as
hypoxic. The Yang mRNA signature performed similarly in
predicting benefit from having CON for LRFS (HR= 0.47, 95% CI
0.25–0.91, p= 0.019) and OS (HR= 0.47, 95% CI 0.24–0.92, p=
0.025) in 65 of the 130 patients it classified as hypoxic. For the 25
patients classified as hypoxic by both signatures, the predictive
benefit (based on the lower HRs) from having CON was higher for
LRFS (HR= 0.29, 95% CI 0.097–0.85, p= 0.017) and OS (HR= 0.26,
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95% CI 0.08–0.82, p= 0.014). The interaction between the hypoxia
status and treatment arms was significant for LRFS (p= 0.033) and
borderline significant for OS (p= 0.065). When categorising based
on both signatures, there was a highly significant association with
CA9 (p= 0.0008) and HIF-1α (p= 0.007) protein expression.
DISCUSSION
A hypoxia-associated miRNA signature was derived that predicted
benefit from CON in patients with MIBC recruited in the Phase 3
BCON trial with trends for positive tests for interactions. The
signature was associated with the protein expression of CAIX and
HIF-1α confirming its hypoxia relevance. The miRNA did not
outperform our mRNA signature, but a combination was superior.
Combining the miRNA signature with our previously derived 24-gene
mRNA classifier identified a small group of patients (25/130) who
derived considerable benefit from hypoxia-modifying treatment.
The ability of the miRNA signature to predict benefit from
hypoxia-modifying CON is consistent with our previous work with
mRNA signatures in not only bladder cancer9 but also laryngeal
tumours.7 Together these findings provide evidence that the most
hypoxic tumours are most responsive to CON across tumour types.
It was not feasible to compare the performance of the miRNA
hypoxia signature with CAIX and HIF-1α given protein expression
data were available for only 84 patients with miRNA expression
data. However, CAIX and HIF-1 α have been shown previously to















































































































































































































































































































































































































































































































































































































































Fig. 1 Boruta plot showing that 19 of the 59 miRNA seed genes are important in predicting the Winter mRNA signature classification of
hypoxia and normoxia in TCGA BLCA samples. Importance is represented by Z-scores. Blue colour boxplots represent Z-scores for the
maximum, mean and minimum shadow features. The boxplots in green indicate features (miRNAs) classified as important. The features in red
were classified as unimportant and the important of the features in yellow could not be determined at the end of 1000 iterations. Importance
classification is relative to the shadowMax. TCGA BLCA The Cancer Genome Atlas bladder cancer.
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Different approaches are used for generating signatures
associated with tumour hypoxia. Here we combined a
widely used seed gene method with the one used previously
to identify hypoxia-related miRNAs by associating with mRNA
classifications.36,37 Although miRNAs can have a tissue-specific
response to hypoxia, some miRNAs are consistently regulated by
hypoxia across tumour types.40 Nine of the 62 miRNA seed genes
used to develop our bladder signature were among the 23
miRNAs identified as hypoxia regulated in breast and colon cancer
cell lines.41 All 14 miRNAs in the signature had been studied in
relation to hypoxia with 12 induced in cancer cell lines,18,42–46 1
(miR-190a-5p) in pulmonary endothelial cells47 and miR-28-5p was
downregulated in mice PC-12 cells.48 miR-210-3p is the most
widely known hypoxia-associated miRNA; it is both induced by
and stimulates the stabilisation of HIF-1α.49 miR-210-3p regulates
the cell cycle, DNA repair, metabolism and angiogenesis during
hypoxia.49 miR-210-3p was an independent prognostic factor in
breast, head and neck and colorectal cancers but not in bladder
cancer.50–53 miR-21-5p is another prominent hypoxia-associated
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Fig. 2 Performance of a 14-miRNA signature in the training and test datasets with stratification by median signature scores.
Kaplan–Meier curves for overall survival in the training (a) and test (b) data sets and for progression-free survival in the training (c) and test (d)
data sets. Patients were stratified by the median of the 14-miRNA signature score. TCGA BLCA The Cancer Genome Atlas bladder cancer.

















FDR false discovery rate.
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oncogenic miRNA in the signature54 that is associated with a poor
prognosis in bladder cancer.55 miR-193b-3p is in a six-miRNA
NMIBC hypoxia signature.18
KEGG pathways associated with the predicted targets of the 14
miRNAs showed that PI3K/Akt signalling was one of the most
significantly enriched. Of note, HIF-1 is a protein downstream of
the PI3K/Akt signalling pathway.56 Regulation of PTEN gene
transcription was also enriched, and PTEN loss promotes HIF-1
transcriptional activity.57 Under hypoxia, RUNX1 interacts with HIF-
1α stimulating the expression of RUNX1-regulated genes con-
tributing to hematopoietic stem cell differentiation.58 The path-
way analysis, therefore, adds further support for the hypoxia
relevance of our miRNA signature.
The miRNA hypoxia signature was not prognostic in the mainly
NMIBC patient bladder cancer cohort. Given the differences in
molecular alterations between the two subtypes of bladder cancer
and involvement of different miRNAs in both subtypes, a MIBC
miRNA signature may not perform in a mainly NMIBC cohort.59,60
The NMIBC signature showed mixed performance in MIBC cohorts
as it was prognostic in the mainly MIBC TCGA BLCA cohort but was
not predictive or prognostic in the RT arm of BCON or the 62-
patient MIBC cohort.
The signature outperformed use of a single miRNA in its ability
to predict benefit from CON highlighting the importance of
developing signatures rather than individual genes as biomarkers.
However, the signature did not outperform our 24-gene mRNA
signature possibly because it had fewer genes. Combining the two
signatures identified the patients who were the most hypoxic. The
combined power of mRNA–miRNA signatures has been shown
previously. A combined mRNA–miRNA leucocyte-associated sig-
nature was more prognostic than the individual signatures for
survival in TCGA ovarian cancer cohort.61
A limitation of our study was the mixed performance of the
signature in surgically treated MIBC despite tumour hypoxia being
associated with a poor prognosis in cancer patients whether
treated by primary surgery or RT.9 Another limitation of the miRNA
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Fig. 3 Performance of a 14-miRNA signature in the training and test datasets with stratification by the upper quartile of signature scores.
Kaplan–Meier curves for local relapse-free (a, b) and overall (c, d) survival for patients with tumours classified as hypoxic and normoxic
stratified by the upper quartile of the 14-miRNA signature score. BCON Bladder Carbogen and Nicotinamide, RT radiotherapy, CON
carbogen–nicotinamide.
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hypoxia signature was that the initial predetermined median cut-
off identified in the TCGA training cohort did not perform
consistently, and hence we changed to using an upper quartile,
which was identified in the 62-patient MIBC cohort. Finding cut-
offs that are robust across a range of data sets with expression
profiling using a range of different technologies was a challenge.
This challenge could be addressed if more data sets were available
particularly those involving RT. In summary, a 14-miRNA hypoxia
signature was developed that predicted benefit from having
hypoxia modifying with RT for patients with MIBC. Combining the
miRNA with our 24-gene mRNA signature identified a small group
of patients who derived considerable benefit from hypoxia
modification. Future work should focus on combining hypoxia
classifications from both signatures to identify patients with the
most hypoxic tumours. The next step to validate the miRNA
hypoxia signature is to test its performance in combination with
the mRNA hypoxia signature in a prospective clinical trial.
Table 2. Top 10 most enriched Reactome pathways for miRNA target
protein-coding genes.
Reactome pathways No. of genes FDR
PI5P, PP2A and IER3 regulate PI3K/AKT signalling 17 0
PIP3 activates AKT signalling 15 0
Constitutive signalling by aberrant PI3K in cancer 14 0
Circadian clock 12 0
Oncogene-induced senescence 9 0
PI3K events in ERBB2 signalling 6 0.0008
Activated NTRK2 signals through FRS2 and FRS3 6 0.0008
Regulation of RUNX1 expression and activity 6 0.0008
Regulation of PTEN gene transcription 13 0.0008
EPHA-mediated growth cone collapse 9 0.0008
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Fig. 4 Combining miRNA and mRNA signatures improves performance. Kaplan–Meier curves for local relapse-free survival for patients with
tumours classified as hypoxic using the miRNA signature (a), the Yang mRNA signature (b) and both signatures (c). Kaplan–Meier curves for
overall survival for patients with tumours classified as hypoxic using the miRNA signature (d), the Yang mRNA signature (e) and both
signatures (f). BCON Bladder Carbogen and Nicotinamide, RT radiotherapy, CON carbogen–nicotinamide.
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